Creo Medical has reported it audited results for the year ending 30 June 2017 (FY17). We note an underlying EBITDA loss of £5.6m versus our expected loss of £5.7m and a closing cash balance of £13.7m. During the year the company has announced a number of achievements for its CROMA platform including first in human data and (post-period end) the FDA clearance for the Speedboat RS2 device and CROMA platform. We maintain our Buy recommendation.
14 Nov 2017
In-line with expectations
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In-line with expectations
Creo Medical Group Plc (CREO:LON) | 34.8 0.1 0.7% | Mkt Cap: 125.6m
- Published:
14 Nov 2017 -
Author:
Chris Donnellan -
Pages:
5
Creo Medical has reported it audited results for the year ending 30 June 2017 (FY17). We note an underlying EBITDA loss of £5.6m versus our expected loss of £5.7m and a closing cash balance of £13.7m. During the year the company has announced a number of achievements for its CROMA platform including first in human data and (post-period end) the FDA clearance for the Speedboat RS2 device and CROMA platform. We maintain our Buy recommendation.